Summary
Eli Lilly & Company (LLY) filed an 8-K on July 22, 2004, to report its financial results for the second quarter and the first six months of 2004. The report highlights the company's use of non-GAAP financial measures, such as adjusted net income and diluted earnings per share, to provide investors with a clearer view of ongoing operational performance. These adjusted figures exclude certain significant and variable items, including asset impairment charges, R&D acquisition costs, and restructuring charges from prior periods. Management believes these non-GAAP measures are crucial for understanding underlying business trends and making meaningful period-over-period comparisons. The adjusted results aim to remove the impact of events that are difficult to predict and can substantially affect reported financial performance. Investors are advised to consider these non-GAAP measures alongside, but not as a substitute for, standard GAAP financial statements when evaluating the company's operational health and future prospects.
Key Highlights
- 1Announcement of second quarter and six-month 2004 financial results.
- 2Company utilizes non-GAAP financial measures (adjusted net income, adjusted EPS) for reporting.
- 3Non-GAAP measures exclude asset impairment charges from Q2 2004.
- 4Non-GAAP measures exclude acquired in-process R&D charges from Q1 2004 (Applied Molecular Evolution acquisition).
- 5Non-GAAP measures exclude asset impairments, restructuring, and special charges from Q1 2003.
- 6Management asserts non-GAAP measures aid in evaluating ongoing operations and making period-over-period comparisons.
- 7Press release and related financial statements attached as Exhibit 99.